ANP Insider Trading (Antisense Therapeutics)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$57,582.16
Insider Selling (Last 12 Months): A$0.00
Antisense Therapeutics Share Price & Price History
Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET
Investor Alert: Argentina Loaded With "White Gold" Opportunity
From Investing Trends | Ad
Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And one small-cap company just snagged a large lithium deposit in a renowned South American location.
Read about this once-in-a-lifetime opportunity
Antisense Therapeutics Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
4/28/2022 | Mark Diamond | Insider | Buy | 244,687 | A$0.11 | A$26,915.57 | | |
12/22/2021 | Mark Diamond | Insider | Issued | 470,549 | A$0.24 | A$112,931.76 | | |
11/8/2021 | Charmaine Gittleson | Insider | Buy | 133,333 | A$0.23 | A$30,666.59 | | |
12/3/2020 | Robert Moses | Insider | Issued | 90,201 | A$0.10 | A$9,020.10 | | |
12/23/2019 | Graham Mitchell | Insider | Issued | 7,000,000 | A$0.09 | A$609,000.00 | | |
12/20/2019 | Robert Moses | Insider | Buy | 100,000 | A$0.09 | A$8,800.00 | | |
12/18/2019 | Graham Mitchell | Insider | Exercise | 48,036 | A$0.08 | A$3,842.88 | | |
12/16/2019 | Robert Moses | Insider | Buy | 618,888 | A$0.08 | A$49,511.04 | | |
12/3/2019 | Robert Moses | Insider | Buy | 800,000 | A$0.08 | A$64,000.00 | | |
Crypto Millionaire: “Pay Attention to May 20th”
From Investor Place Media | Ad
Charlie Shrem is like the “Godfather of Cryptocurrencies”. He discovered Bitcoin when it was trading for $5. Ethereum at $109. Binance at just $6. Cardano for 5 CENTS.
Today, he’s sharing the details of a $0.21 CENT crypto with Top 5 Potential… as well as his BIG prediction for May 20th.
Get the details NOW.
SEC Filings (Institutional Ownership Changes) for Antisense Therapeutics (ASX:ANP)
Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.
Read More on Antisense Therapeutics
Today's Range
Now: N/A
50 Day Range
MA: N/A
52 Week Range
Now: N/A
Volume
1,318,309 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Antisense Therapeutics?